title: Increased plasma levels of human interleukin for DA1.a cells/leukemia inhibitory factor in sepsis correlate with shock and poor prognosis.
abstract: Animal study results have suggested a role in sepsis for human interleukin for DA1.a cells/leukemia inhibitory factor (HILDA/LIF). HILDA/LIF and interleukin-6 (IL-6) levels were prospectively studied by serial ELISAs in 34 septic patients. HILDA/LIF was detected in 11 of 34 patients at plasma levels of 100-37,000 pg/mL. Peak HILDA/LIF levels correlated with increased temperature and creatinine and IL-6 and with decreased arterial CO2 (P < .05). Multivariate analysis showed that shock and decreased arterial CO2 accounted for 75% of peak HILDA/LIF plasma variations (R2 = .753). Fatal outcome was most often associated with detectable HILDA/LIF (> 56 pg/mL) and peak IL-6 plasma levels > 850 pg/mL (sensitivity, 83%; specificity, 87%), but both (at respective levels of > 480 and > 850 pg/mL) were associated with fatal outcome. HILDA/LIF was detected in septic patients exhibiting shock, and its levels correlated with higher mortality and shorter survival.
authors.affiliation: Service de Réanimation Médicale, Laboratoire de Statistiques et d'Informatique Médicale (CHU Hôtel-Dieu), Institut National de la Santé et de la Recherche Médicale (U211), Nantes, France.
authors.forename: D
authors.initials: D
authors.lastname: Villers
authors.forename: T
authors.initials: T
authors.lastname: Dao
authors.forename: J M
authors.initials: JM
authors.lastname: Nguyen
authors.forename: E
authors.initials: E
authors.lastname: Bironneau
authors.forename: A
authors.initials: A
authors.lastname: Godard
authors.forename: M
authors.initials: M
authors.lastname: Moreau
authors.forename: D
authors.initials: D
authors.lastname: De Groote
authors.forename: F
authors.initials: F
authors.lastname: Nicolas
authors.forename: J P
authors.initials: JP
authors.lastname: Soulillou
authors.forename: I
authors.initials: I
authors.lastname: Anegon
mesh_terms: D018806:APACHE; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006131:Growth Inhibitors / Q000097:blood*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012772:Shock, Septic / Q000276:immunology* / Q000401:mortality; D016019:Survival Analysis; D018746:Systemic Inflammatory Response Syndrome / Q000276:immunology* / Q000401:mortality
chemical_list: D006131:Growth Inhibitors; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines